The effect of adjuvant aromatase inhibitors on BMD in women with breast cancer

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11

Contributing Authors: PE Goss DL Hershman AM Cheung JN Ingle S Khosla V Stearns H Chalchal K Rowland HB Muss HM Linden J Scher KI Pritchard CR Elliott T Badovinac-Crnjevic J St Louis JA Chapman LE Shepherd

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

497 postmenopausal women with hormone-receptor-positive breast cancer were randomized to receive adjuvant exemestane 25 mg or anastrozole 1 mg daily for 5 years. Two subgroups were identified: those with baseline T-scores of -2.0 or greater at the spine and hip (subgroup 1), and those with baseline T-scores less than -2.0 at the spine and hip and taking bisphosphonates (subgroup 2). Results at 2 y...